DiaMedica to Deliver Poster Presentation at World Conference on Clinical Pharmacology and Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and development company
focused on novel treatments for Type 2 diabetes, announces that it will be
presenting results of a study at the 9th World Conference on Clinical
Pharmacology and Therapeutics (www.cpt2008.org) in Quebec City, Canada today.


The presentation, entitled "Reversing Prediabetes Insulin Resistance by Synergy
of Drugs Mimicking a Feeding Signal" highlights the preclinical data from the
Company's lead drug candidate, DM-71. DM-71 is a novel combination of
Bethanechol and N-Acetyl Cysteine, two compounds with a strong safety profile
that function in a synergistic manner to replace the function of a
parasympathetic nerve signal to the liver. Neither compound is able to restore
insulin sensitivity on its own, but when combined, insulin sensitivity is
restored to near control levels. DiaMedica has demonstrated in previous
preclinical studies that when this particular nerve signal is impaired it
compromises the ability of insulin to regulate glucose metabolism.


"The preclinical study used a model of diabetes caused by voluntary consumption
of sucrose rather than genetically or chemically induced diabetes in order to
more closely represent the human disease", stated Dr. Wayne Lautt, Chief
Scientific Officer of DiaMedica. "The study demonstrated that a one time dose of
DM-71 can restore the ability to process the nutrients from a meal when the
parasympathetic nerve to the liver is completely dysfunctional. These results
provide the mechanistic understanding for the recent successful Phase IIa proof
of concept clinical trials reported by DiaMedica".


About DiaMedica

DiaMedica is a biotechnology company developing novel treatments for various
stages of Type 2 diabetes with three clinical stage products. The Company's lead
product, DM-71, demonstrated the ability to reduce HbA1c levels and weight in a
Phase IIa human trial. DM-83 showed efficacy in reducing insulin levels in a
Phase IIa meal tolerance test. DiaMedica's third clinical stage product is
entering a Phase IIa trial in the second half of 2008. DiaMedica trades under
the symbol "DMA" on the TSX Venture Exchange. For additional information please
visit the Company's website at www.diamedica.com.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: DiaMedica's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in DiaMedica's filings with Canadian securities regulatory
authorities, as well as DiaMedica's ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well as under the
heading "Risk Factors" contained in DiaMedica's final long-form prospectus dated
March 12, 2007. DiaMedica cautions that the foregoing list of important factors
that may affect future results is not exhaustive. When relying on DiaMedica's
forward-looking statements to make decisions with respect to DiaMedica,
investors and others should carefully consider the foregoing factors and other
uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, DiaMedica
cannot provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to update or
revise any forward-looking statement.